Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

NCT01782976 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Cilengitide
DRUG: Bevacizumab
BEHAVIORAL: Questionnaire

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]